Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer center

Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer center

Background: Head-and-neck squamous cell cancers (HNSCC) are common in India. Recurrent and metastatic HNSCC carry a poor prognosis. The chemotherapy options are limited, and the median survival is measured in months. The addition of targeted antibodies and immunotherapy improves overall survival (OS...

Full description

Bibliographic Details
Main Authors: Rup J Sarma, Vijay M Patil, Alok Shetty, Nandini Menon, Vanita Noronha, Kumar Prabhash
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2022-01-01
Series:Cancer Research, Statistics, and Treatment
Subjects:
head and neck cancer
hnscc
oral cancer
platinum refractory
Online Access:http://www.crstonline.com/article.asp?issn=2590-3233;year=2022;volume=5;issue=4;spage=630;epage=637;aulast=Sarma

Internet

http://www.crstonline.com/article.asp?issn=2590-3233;year=2022;volume=5;issue=4;spage=630;epage=637;aulast=Sarma

Similar Items